@article{71eb98e8b0f14d0f90e1b1c43f101ca0,
title = "Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies",
abstract = "Background and Objective: Patients with dementia with Lewy bodies (DLB) may have overlapping Alzheimer's disease pathology. We investigated the longitudinal rate of tau accumulation and its association with neurodegeneration and clinical disease progression in DLB. Methods: Consecutive patients with probable DLB (n = 22) from the Mayo Clinic Alzheimer's Disease Research Center and age-matched and sex-matched cognitively unimpaired controls (CU; n = 22) with serial magnetic resonance imaging and flortaucipir positron emission tomography scans within an average of 1.6 years were included. Regional annualized rates of flortaucipir uptake standardized uptake value ratios (SUVr) were calculated. Regional annualized rates of cortical volume change were measured with the Tensor Based Morphometry–Syn algorithm. Results: The annual increase of flortaucipir SUVr was greater in the middle and superior occipital, fusiform, and inferior parietal cortices in DLB (mean: 0.017, 0.019, 0.019, and 0.015, respectively) compared with the CU (mean: −0.006, −0.009, −0.003, and − 0.005, respectively; P < 0.05). In patients with DLB (but not the CU), a longitudinal increase in flortaucipir SUVr was associated with longitudinal cortical atrophy rates in the lateral occipital and inferior temporoparietal cortices, hippocampus, and the temporal pole as well as a concurrent decline on Mini-Mental State Examination and Clinical Dementia Rating–Sum of Boxes in the lateral occipital and the fusiform cortices. Conclusions: Tau accumulation was faster in DLB compared with the CU, with increased accumulation rates in the lateral occipital and temporoparietal cortices. These increased rates of tau accumulation were associated with neurodegeneration and faster disease progression in DLB. Tau may be a potential treatment target in a subset of patients with DLB.",
keywords = "PET, dementia with Lewy bodies, longitudinal, neurodegeneration, tau",
author = "Qin Chen and Przybelski, {Scott A.} and Senjem, {Matthew L.} and Schwarz, {Christopher G.} and Lesnick, {Timothy G.} and Hugo Botha and Knopman, {David S.} and Jonathan Graff-Radford and Rodolfo Savica and Jones, {David T.} and Fields, {Julie A.} and Jain, {Manoj K.} and Graff-Radford, {Neill R.} and Ferman, {Tanis J.} and Kremers, {Walter K.} and Jack, {Clifford R.} and Petersen, {Ronald C.} and Boeve, {Bradley F.} and Lowe, {Val J.} and Kejal Kantarci",
note = "Funding Information: Q.C. receives the Alzheimer's Association International Conference (AAIC) travel fellowship bursary to attend the AAIC conference in 2018 and research support from National Natural Science Foundation of China (8207052203). C.G.S. receives research support from National Institutes of Health (NIH) and has received payment from Karolinska Institute for a lecture. H.B. receives research support from the NIH and National Institute on Aging (NIA) paid to Mayo Clinic (R01 DC12519‐06, NIH/National Institute on Deafness and Other Communication Disorders (NIDCD), Co‐I; U19 AG63911‐02, NIA, Co‐I; P30 AG62677‐02, NIA, study staff; RO3 NS114365‐01, NIA, Co‐investigator (Co‐I)). D.S.K. serves on the Data and Safety Monitoring Board (DSMB) of the Dominantly Inherited Alzheimer Network Trial Unit (DIAN‐TU) study for a Biogen tau drug (Mayo Clinic receives the consulting fees and he has no control over those funds) and for Agenebio (no consulting fees). He is a site primary investigator (PI) for clinical trials sponsored by Biogen, Lilly, and the University of Southern California and is funded by the NIH. J.G.‐R. receives research support from the NIH. He serves on American Academy of Neurology committee and has consulted for American Academy of Neurology (AAN) J.A.F. receives research support from the NIH. She was sponsored by the Study of Women's Health Across the Nation (SWAN)‐Aging Oversight and Monitoring Board and University of Pittsburgh. M.K.J. holds the stock of Eli Lily. T.J.F. receives funding from the Mangurian Foundation for Lewy body research and the NIH. W.K.K. receives research funding from AstraZeneca, Biogen, Roche, and the NIH. C.R.J. serves on an independent data monitoring board for Roche and has served as a speaker for Eisai and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from the NIH, the GHR Foundation, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. R.C.P. serves on scientific advisory boards for Genentech; consulted for Roche, Merck, Biogen, and Eisai; and receives royalties from publishing (Oxford University Press, 2003). He also receives research support from the NIH. B.F.B. has served as an investigator for clinical trials sponsored by GE Healthcare and Axovant. He receives royalties from the publication of a book titled (Cambridge Medicine, 2009, 2017). He serves on the scientific advisory board of the Tau Consortium. He receives research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, and the Little Family Foundation. V.J.L. has consulted for Life Molecular Imaging, Avid Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, Avid Radiopharmaceuticals, and the NIH (NIA, National Cancer Institue (NCI)). K.K. serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc. and the data monitoring boards of Pfizer and Janssen Alzheimer Immunotherapy. She receives research support from Avid Radiopharmaceuticals and Eli Lilly. She is funded by the Alzheimer's Drug Discovery Foundation and the NIH. S.A.P., M.L.S., T.G.L., R.S., and N.R.G.‐R. have nothing to disclose. Mild Cognitive Impairment Behavioral Neurology of Dementia Funding Information: This work is supported by the National Institutes of Health Grants U01 NS100620, P50 AG016574, and P30 AG 062677; Foundation Dr. Corinne Schulerand; Mangurian Foundation for Lewy Body Research; Elsie and Marvin Dekelboum Family Foundation; Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program; Little Family Foundation; and LBD Functional Genomics Program. Funding agencies: Publisher Copyright: {\textcopyright} 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society",
year = "2022",
doi = "10.1002/mds.28973",
language = "English (US)",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
}